ArticleBMC oral health2026
Effect of bone marrow stem cell conditioned medium on amiodarone-induced submandibular salivary gland and kidney damage in male albino rats.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThis study aimed to demonstrate the histological changes in the submandibular salivary glands (SMSGs) and kidneys induced by Amiodarone in albino rats, and to assess the potential therapeutic effects of bone marrow stem cells conditioned medium (BMSCs-CM).
methodsThirty adult male Sprague Dawley Albino rats (180–230 g, aged 3–4 months, were arbitrarily divided into three equal groups. Group I (control): received a balanced diet and water for six days without medication. Group II (Amiodarone Group): was administered Amiodarone intraperitoneally at 50 mg/kg/day for six days. Group III (Conditioned media (CM) Group): received the same treatment as Group II, followed by intravenous injection of 1 ml BMSCs-CM for four consecutive days. At the end of the experiment, all rats were euthanized, and salivary gland and kidney samples were collected for histological analysis using hematoxylin and eosin (H&E), Masson's trichrome, and caspase 3 staining. ELISA was used to quantify tissue levels of malondialdehyde (MDA) and catalase (CAT).
resultsHistologically, Group III's findings were almost resembled to those of Group I, with normal SMSG and kidney features. Group III salivary glands showed lower MDA levels (17.47 ± 0.58) compared to the Amiodarone treated samples (24.17 ± 1.72) and greater CAT levels (60 ± 5.06) compared to the Amiodarone group (35.33 ± 2.73). Administration of CM significantly increased CAT (23.66 ± 1.36) and decreased MDA levels in kidney samples (5.53 ± 0.31) as compared to the Amiodarone group.
conclusionsBMSCs-CM has anti-inflammatory and anti-oxidative properties. Administering BMSCs-CM serve as cell-free therapy to treat the SMSGs and kidney damage caused by Amiodarone toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.